MiNK Therapeutics, Inc.(INKT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

INKT MiNK Therapeutics, Inc.

Closed 09-23 16:00:00 EDT

12.35

+0.24

+1.98%

盘后12.35

+0.000.00%

19:30 EDT

High12.50	Low11.68	Vol14.81K
Open12.50	D1 Closing12.11	Amplitude6.77%
Mkt Cap63.02M	Tradable Cap25.61M	Total Shares5.10M
T/O179.98K	T/O Rate0.71%	Tradable Shares2.07M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"INKT","market":"US","secType":"STK","nameCN":"MiNK Therapeutics, Inc.","latestPrice":12.35,"timestamp":1790193600000,"preClose":12.11,"halted":0,"volume":14809,"hourTrading":{"tag":"盘后","latestPrice":12.35,"preClose":12.35,"latestTime":"19:30 EDT","volume":119,"amount":1372.21,"timestamp":1790206202114,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.0198183319570603,"floatShares":2073300,"shares":5103000,"eps":-2.39704,"marketStatus":"Closed","change":0.24,"latestTime":"09-23 16:00:00 EDT","open":12.5,"high":12.5,"low":11.6801,"amount":179976.38338400002,"amplitude":0.067704,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.39704,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1790236800000},"marketStatusCode":5,"adr":0,"listingDate":1634270400000,"exchange":"NASDAQ","adjPreClose":12.11,"preHourTrading":{"tag":"盘前","latestPrice":12.64,"preClose":12.11,"latestTime":"09:28 EDT","volume":1025,"amount":12803.040275000001,"timestamp":1790170131256,"change":0.53,"changeRate":0.043765,"amplitude":0.044591},"postHourTrading":{"tag":"盘后","latestPrice":12.35,"preClose":12.35,"latestTime":"19:30 EDT","volume":119,"amount":1372.21,"timestamp":1790206202114,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.66877},"requestUrl":"/m/hq/s/INKT/","defaultTab":"news","newsList":[{"id":"2659215183","title":"MiNK Therapeutics Q2 Loss Narrows on Expense Discipline","url":"https://stock-news.laohu8.com/highlight/detail?id=2659215183","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659215183?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:40","pubTimestamp":1786621208,"startTime":"0","endTime":"0","summary":"MiNK Therapeutics Q2 loss narrows on expense disciplineOverviewUS biopharma firm's Q2 net loss narrowed yr/yr, reflecting continued expense disciplineCompany advanced lead cell therapy agenT-797 into ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A0I6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4539","SANA","PROK","IPSC","INKT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659597551","title":"MiNK Therapeutics Q2 EPS $(0.62) Misses $(0.60) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2659597551","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659597551?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:32","pubTimestamp":1786620751,"startTime":"0","endTime":"0","summary":"MiNK Therapeutics (NASDAQ:INKT) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0.60) by 3.33 percent. This is a 41.51 percent increase over losses of $(1.06) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61169935/mink-therapeutics-q2-eps-0-62-misses-0-60-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659159467","title":"MiNK Therapeutics Q2 EPS USD -0.62","url":"https://stock-news.laohu8.com/highlight/detail?id=2659159467","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659159467?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:31","pubTimestamp":1786620660,"startTime":"0","endTime":"0","summary":"BRIEF-MiNK Therapeutics Q2 EPS USD -0.62Aug 13 (Reuters) - MiNK Therapeutics Q2 net income USD -3.1 million.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nPLXXH2Z3K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659159908","title":"Mink Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of Agent-797 in Acute Lung Injury","url":"https://stock-news.laohu8.com/highlight/detail?id=2659159908","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659159908?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:30","pubTimestamp":1786620600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nTUA3RMZGJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["INKT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659159294","title":"Press Release: MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury","url":"https://stock-news.laohu8.com/highlight/detail?id=2659159294","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659159294?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:30","pubTimestamp":1786620600,"startTime":"0","endTime":"0","summary":"-- First patients treated in randomized Phase 2 trial C-1300-02 were alive. at Day 28, with improved oxygenation, resolution of ARDS with return to. -- Clinical recovery and biologic readouts moved in the same direction;serum and bronchoalveolar lavage analyses showed reduced inflammatory. markers and biologic changes associated with immune recovery and tissue. repair; no major serious adverse events were attributed to agenT-797. -- Launched international paid named-patient access program established for. physicians to request access to agenT-797, subject to per-patient","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4018","BK4139","INKT","ODC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658918266","title":"Mink Therapeutics Inc Expected to Post a Loss of 60 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2658918266","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658918266?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:50","pubTimestamp":1786452606,"startTime":"0","endTime":"0","summary":"Mink Therapeutics Inc <INKT.OQ> expected to post a loss of60cents a share - Earnings PreviewMink Therapeutics IncINKT.OQINKT.Ois expected to  show no change in quarterly revenue when it reports  results on August 13 for the period ending June 30 2026LSEG's mean analyst estimate for Mink Therapeutics Inc is for a loss of 60 cents per share.The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\"The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for Mink Therapeutics Inc is $39.00, about 256.2% above its last closing price of $10.95This summary was machine generated August 11 at 12:50 GMT.  All figures in US dollars unless otherwise stated.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nL8N44815O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657691655","title":"Mink Therapeutics - First Agent-797 Patients Alive and Afebrile at Day 28 with Improved Oxygenation","url":"https://stock-news.laohu8.com/highlight/detail?id=2657691655","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657691655?lang=en_us&edition=fundamental","pubTime":"2026-08-07 00:02","pubTimestamp":1786032170,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nFWN4431GD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["INKT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657556386","title":"Mink Therapeutics - no Major Serious Adverse Events Attributed to Agent-797 in First Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2657556386","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657556386?lang=en_us&edition=fundamental","pubTime":"2026-08-07 00:02","pubTimestamp":1786032170,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nFWN4431GD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["INKT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657465569","title":"Mink Therapeutics - Enrollment Continues in Lviv with U.S. Sites Opening; Additional Data Expected Early 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2657465569","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657465569?lang=en_us&edition=fundamental","pubTime":"2026-08-07 00:02","pubTimestamp":1786032170,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nFWN4431GD:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","INKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657655548","title":"MiNK Therapeutics Reports Early Phase 2 Data for agenT-797 in Severe Hypoxemic Pneumonia Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2657655548","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657655548?lang=en_us&edition=fundamental","pubTime":"2026-08-07 00:01","pubTimestamp":1786032113,"startTime":"0","endTime":"0","summary":"MiNK Therapeutics reports early Phase 2 data for agenT-797 in severe hypoxemic pneumonia trialMink Therapeutics presented early Day 28 observations from an ongoing randomized Phase 2 trial of agenT-79","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL3djY3V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657148639","title":"Mink Therapeutics to Report Q2 Results, Host Conference Call and Webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2657148639","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657148639?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:19","pubTimestamp":1786018783,"startTime":"0","endTime":"0","summary":"Mink Therapeutics to report Q2 results, host conference call and webcastMink Therapeutics schedules Q2 2026 results release before the open on Aug. 13, 2026.Conference call, webcast set for Aug. 13, 2","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL25rnvH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2210150020.SGD","BK4585","IE00BGHQF748.EUR","BK4112","SG9999014005.SGD","SG9999014013.SGD","LU2210149790.SGD","LU0314104364.USD","BCDF","INKT","SG9999014039.USD","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","BK4588","SG9999014021.USD","IE00B64PRP62.GBP","IE00BKPKM429.USD","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","NDAQ","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657634393","title":"MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2657634393","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657634393?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:19","pubTimestamp":1786018740,"startTime":"0","endTime":"0","summary":"NEW YORK, Aug.  06, 2026  (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/06/3340265/0/en/MiNK-Therapeutics-to-Report-Second-Quarter-2026-Financial-Results-Provide-Clinical-Updates-on-agenT-797-in-Lung-Injury-and-Highlight-Important-Business-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646361925","title":"MiNK Therapeutics Advances Phase 2 Trial of agenT-797 in Severe Pneumonia: What Investors Should Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2646361925","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646361925?lang=en_us&edition=fundamental","pubTime":"2026-06-27 00:32","pubTimestamp":1782491569,"startTime":"0","endTime":"0","summary":"Mink Therapeutics, Inc. ($INKT) announced an update on their ongoing clinical study. The Phase 2 trial, officially titled “Phase 2 Adaptive Randomi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mink-therapeutics-advances-phase-2-trial-of-agent-797-in-severe-pneumonia-what-investors-should-watch?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mink-therapeutics-advances-phase-2-trial-of-agent-797-in-severe-pneumonia-what-investors-should-watch?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4211","ISBC","BK4139","INKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645583772","title":"MiNK Therapeutics Stockholders Back Directors, Ratify Auditor","url":"https://stock-news.laohu8.com/highlight/detail?id=2645583772","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645583772?lang=en_us&edition=fundamental","pubTime":"2026-06-23 23:15","pubTimestamp":1782227733,"startTime":"0","endTime":"0","summary":"MiNK Therapeutics ( ($INKT) ) has shared an update. MiNK Therapeutics held its Annual Meeting of Stockholders on June 17, 2026, with 3,277,906 shar...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mink-therapeutics-stockholders-back-directors-ratify-auditor?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mink-therapeutics-stockholders-back-directors-ratify-auditor?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","INKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645072834","title":"Mink Therapeutics shareholders approve KPMG as auditor","url":"https://stock-news.laohu8.com/highlight/detail?id=2645072834","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645072834?lang=en_us&edition=fundamental","pubTime":"2026-06-23 22:11","pubTimestamp":1782223868,"startTime":"0","endTime":"0","summary":"Mink Therapeutics held its annual stockholder meeting on June 17, 2026.Stockholders backed the slate of Class II director nominees for three-year terms ending at the 2029 annual meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mink Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 23, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nNDL6wTDy6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641125057","title":"MiNK Therapeutics Rocked by Fresh Insider Share Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2641125057","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641125057?lang=en_us&edition=fundamental","pubTime":"2026-06-06 10:08","pubTimestamp":1780711716,"startTime":"0","endTime":"0","summary":"New insider activity at MiNK Therapeutics ( ($INKT) ) has taken place on June 5, 2026. Director Barbara Ryan has recently sold 1,500 shares of MiNK...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/mink-therapeutics-rocked-by-fresh-insider-share-sale-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/mink-therapeutics-rocked-by-fresh-insider-share-sale-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["INKT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641128246","title":"MiNK Therapeutics director Barbara Ryan disposes of 1,500 common shares worth $19,143.25","url":"https://stock-news.laohu8.com/highlight/detail?id=2641128246","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641128246?lang=en_us&edition=fundamental","pubTime":"2026-06-06 06:04","pubTimestamp":1780697076,"startTime":"0","endTime":"0","summary":"Mink Therapeutics director Barbara Ryan sold 1,500 shares of common stock on June 4, 2026.Sales priced at USD 12.68 to USD 12.8 per share.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mink Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 05, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260605:nNDL2NmN4N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"MiNK Therapeutics director Barbara Ryan disposes of 1,500 common shares worth $19,143.25","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INKT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640181711","title":"MiNK Therapeutics announces virtual annual shareholders meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2640181711","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640181711?lang=en_us&edition=fundamental","pubTime":"2026-06-04 04:32","pubTimestamp":1780518738,"startTime":"0","endTime":"0","summary":"Mink Therapeutics will hold its 2026 annual shareholders meeting in a virtual-only format on June 17, 2026.The company will provide a live webcast of the meeting, with a replay available afterward.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nNDLhYp6r:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU2210150020.SGD","NDAQ","BK4112","SG9999014039.USD","IE00BN0W2V16.EUR","SG9999014013.SGD","IE00B64PRP62.GBP","LU2095319765.USD","SG9999014021.USD","BK4585","IE00B3QW5Z07.USD","LU2210149790.SGD","LU0314104364.USD","BK4139","IE00BN0W2T93.GBP","INKT","IE00BN0W2W23.USD","IE00BGHQF748.EUR","IE00BKPKM429.USD","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640588184","title":"MiNK Therapeutics Announces its Virtual 2026 Annual Shareholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2640588184","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640588184?lang=en_us&edition=fundamental","pubTime":"2026-06-04 04:30","pubTimestamp":1780518600,"startTime":"0","endTime":"0","summary":"NEW YORK, June  03, 2026  (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc.(NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/03/3306402/0/en/MiNK-Therapeutics-Announces-its-Virtual-2026-Annual-Shareholders-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INKT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639690209","title":"BUZZ-U.S. STOCKS ON THE MOVE-Snowflake, Best Buy, Kohl's","url":"https://stock-news.laohu8.com/highlight/detail?id=2639690209","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639690209?lang=en_us&edition=fundamental","pubTime":"2026-05-29 01:41","pubTimestamp":1779990094,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Snowflake, Best Buy, Kohl'sWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: ht","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nL6N4250NZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HPQ","SIDU","HLXX","D","HRL","DLTR","SNOW","MOD","TSN","AU","BURL","LLY","CGTL","AVEX","NEMG","P","SNPS","SUGP","DAVE","UNP","NEE","HL","ZCMD","PLAB","XOM","APA","NSC","UMAC","NEBX","BBY","SNOU","NEM","KSS","SPRC","CRM","BTU","MASK","INKT","COGT","AMPX","NBIS","NEOV","A","MMM","CDE","PWR","CZR","CVX","FANG","MRVL"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.minktherapeutics.com;investor.minktherapeutics.com","stockEarnings":[{"period":"1week","weight":0.0613},{"period":"1month","weight":-0.0074},{"period":"3month","weight":0},{"period":"6month","weight":0.2575},{"period":"1year","weight":-0.2571},{"period":"ytd","weight":0.0861}],"compareEarnings":[{"period":"1week","weight":0.0211},{"period":"1month","weight":0.01},{"period":"3month","weight":0.0547},{"period":"6month","weight":0.1989},{"period":"1year","weight":0.1598},{"period":"ytd","weight":0.1341}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company has a collaboration with autonomous therapeutics, inc. to develop novel therapies targeting metastatic tumors. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.041395},{"month":2,"riseRate":0.2,"avgChangeRate":-0.047548},{"month":3,"riseRate":0,"avgChangeRate":-0.079206},{"month":4,"riseRate":0.4,"avgChangeRate":0.010238},{"month":5,"riseRate":0,"avgChangeRate":-0.080325},{"month":6,"riseRate":0.4,"avgChangeRate":0.018096},{"month":7,"riseRate":0.2,"avgChangeRate":0.152031},{"month":8,"riseRate":0.4,"avgChangeRate":0.128048},{"month":9,"riseRate":0.2,"avgChangeRate":-0.08761},{"month":10,"riseRate":0.5,"avgChangeRate":-0.021174},{"month":11,"riseRate":0.6,"avgChangeRate":-0.066406},{"month":12,"riseRate":0.4,"avgChangeRate":-0.119867}],"exchange":"NASDAQ","name":"MiNK Therapeutics, Inc.","nameEN":"MiNK Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"MiNK Therapeutics, Inc.(INKT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest MiNK Therapeutics, Inc.(INKT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"MiNK Therapeutics, Inc.,INKT,MiNK Therapeutics, Inc.股票,MiNK Therapeutics, Inc.股票老虎,MiNK Therapeutics, Inc.股票老虎国际,MiNK Therapeutics, Inc.行情,MiNK Therapeutics, Inc.股票行情,MiNK Therapeutics, Inc.股价,MiNK Therapeutics, Inc.股市,MiNK Therapeutics, Inc.股票价格,MiNK Therapeutics, Inc.股票交易,MiNK Therapeutics, Inc.股票购买,MiNK Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"MiNK Therapeutics, Inc.(INKT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest MiNK Therapeutics, Inc.(INKT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}